Repatha
Jury upholds Amgen’s patent validity for Repatha, deflecting challenge from Sanofi and Regeneron
February 26, 2019Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, patent, pharma
Amgen is celebrating after a Delaware jury backed the validity of two of its patents against challenges from Regeneron and …
China’s NMPA approves Amgen’s Repatha to reduce cardiovascular event risk
January 25, 2019Medical Communications, Sales and Marketing Amgen, China, Repatha, cardiovascular disease, pharma, stroke
Amgen has announced that its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) has secured approval by China’s drug …
Amgen slashes price of cholesterol drug Repatha by 60%
October 25, 2018Sales and Marketing Repatha, cholestrol, drug, medicine, pricing
American multinational Amgen has slashed the price of cholesterol drug Repatha, reducing the medication’s US list price by 60%. The …
Europe expands approved indication of Amgen’s Repatha in cardiovascular disease
May 17, 2018Sales and Marketing Amgen, Repatha, cardiovascular disease, pharma
Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: …
Sanofi & Regeneron deflect Amgen’s legal marketing block on Praluent
February 9, 2017Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, praluent
Sanofi and Regeneron have successfully won in a US Court ruling calling for the suspension of the permanent injunction of …
Positive Phase III results for Amgen’s Repatha for coronary artery disease
September 21, 2016Research and Development Amgen, Phase III trial, Repatha
Amgen has announced that its monoclonal antibody Repatha (evolocumab) achieved positive Phase III results for the treatment of coronary artery …
Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds
August 17, 2016Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent
A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …
FDA approves single monthly injection of Amgen’s Repatha
July 12, 2016Manufacturing and Production, Sales and Marketing Amgen, FDA, Repatha, pushtronex
Amgen (NASDAQ: AMGN) has announced that the US Food and Drug Administration (FDA) has approved a new, monthly single-dose administration …
NICE recommends Sanofi, Amgen cholesterol drugs
May 6, 2016Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …
Amgen’s high cholesterol drug at centre of patent court case yields positive clinical trial results
April 4, 2016Research and Development, Sales and Marketing Amgen, Repatha, Sanofi, high cholesterol. ldl, ldl-c, phase III, statins
Amgen has announced positive results from the Phase III GAUSS-3 clinical trial evaluating Repatha (evolucumab) in patients with high cholesterol …
Amgen wins high-profile cholesterol drug patent case v Sanofi
March 17, 2016Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent
A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …
NICE changes mind on Amgen’s cholesterol drug
February 8, 2016Manufacturing and Production, Sales and Marketing Amgen, NICE, Repatha
NICE has changed its mind on Amgen’s cholesterol-busting drug Repatha (evolocumab), and decided to recommend approval of the treatment in …
Amgen earns first Japanese nod for PCSK9 inhibitor
January 25, 2016Sales and Marketing Amgen, Astellas, Japan, PCSK9 inhibitor, Repatha, evolocumab, high cholesterol
The Japanese Ministry of Health, Labour and Welfare has approved Amgen’s cholesterol-lowering medication Repatha, in a joint venture between Amgen …
NICE rejects Amgen’s Repatha in draft guidance
November 18, 2015Research and Development, Sales and Marketing Amgen, NICE, Repatha, evolocumab, high cholesterol
NICE has published draft guidance rejecting Amgen’s Repatha as a treatment for people with high cholesterol.
FDA approves Amgen’s cholesterol lowering drug
August 28, 2015Medical Communications, Research and Development Amgen, FDA, Repatha, evolocumab
The FDA has endorsed Amgen’s cholesterol-lowering medication, Repatha, for the use in patients with high cholesterol. It follows Amgen’s successful …
Latest content
Five Facts about cardiovascular disease
